Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma.
Staci L HaneyMichelle L VarneyJacob T WilliamsLynette M SmithGeoffrey TalmonSarah A HolsteinPublished in: Experimental hematology & oncology (2022)
We demonstrate that GGSI/PI treatment can potentiate activation of the UPR and apoptotic pathway, as well as induce upregulation of markers associated with the ICD pathway. Collectively, these findings lay the groundwork for future clinical studies evaluating combination GGSI and PI therapy in patients with MM.